StreetInsider.com News Articles

AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4)

Fri, 23 Oct 2026 17:00:00 -0400

MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced it granted inducement equity awards to two newly-hired employees.

On October 19, 2026, the Compensation Committee granted inducement equity awards to two newly hired employees consisting in the aggregate of options to purchase 10,565 shares of the Company's common stock and 5,283 restricted stock units (RSUs). The options have an exercise price equal to the closing price of the Company's common stock on The Nasdaq Global Market on October 19,

AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4)

Fri, 23 Oct 2026 17:00:00 -0400

AN2 Therapeutics to present Phase 2 epetraborole trial design at MPN congress

Wed, 21 Oct 2026 07:00:29 -0400

AN2 Therapeutics, Inc. (Nasdaq: ANTX) announced it will present a poster detailing the design of a planned Phase 2 clinical trial evaluating epetraborole in patients with polycythemia vera (PV) at the 18th International Congress on Myeloproliferative Neoplasms.

The congress is scheduled for October 29-30, 2026, in Brooklyn, New York. The poster, titled "Phase 2 Study of Oral Epetraborole for Treatment of Phlebotomy-Dependent PV," is set to be presented on October 29, 2026, from 5:45 to 7:15 p.m. ET, as poster number 148.

AN2 Therapeutics is a clinical-stage biopharmaceutical company based in Menlo Park, California, focused on small-molecule therapeutics derived from a boron

AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms

Wed, 21 Oct 2026 07:00:00 -0400

MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced the presentation of a poster detailing the design of its planned Phase 2 clinical trial evaluating epetraborole in patients with polycythemia vera (PV) at the 18th International Congress on Myeloproliferative Neoplasms being held October 29-30, 2026 in Brooklyn, New York.

Poster Session Details
Title: Phase 2 Study of Oral Epetraborole for Treatment of Phlebotomy-Dependent PV
Date: Thursday, October 29, 2026
Time: 5:45-7:15pm ET
Poster number:

AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms

Wed, 21 Oct 2026 07:00:00 -0400

Poster Session Details
Title: Phase 2 Study of Oral Epetraborole for Treatment of Phlebotomy-Dependent PV
Date: Thursday, October 29, 2026
Time: 5:45-7:15pm ET
Poster number:

AN2 Therapeutics to Participate at Upcoming Investor Conferences

Tue, 20 Oct 2026 16:13:00 -0400

MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (NASDAQ: ANTX), a clinical stage biopharmaceutical company discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced company management will participate in three upcoming investor conferences in November.

Details of the events are as follows:

Guggenheim 3rd Annual Healthcare Innovation Conference, November 9-11, 2026

Eric Easom, Co-Founder, Chairman, President and CEO, will participate in a fireside chat on Monday, November 9, 2026 at 9:30am ET, and members of management will be available for 1X1 meetings.

Stifel 2026 Healthcare Conference, November 10-12, 2026

Eric Easom, Co-Founder, Chairman, President and

AN2 Therapeutics to Participate at Upcoming Investor Conferences

Tue, 20 Oct 2026 16:13:00 -0400

Details of the events are as follows:

Guggenheim 3rd Annual Healthcare Innovation Conference, November 9-11, 2026

Eric Easom, Co-Founder, Chairman, President and CEO, will participate in a fireside chat on Monday, November 9, 2026 at 9:30am ET, and members of management will be available for 1X1 meetings.

Stifel 2026 Healthcare Conference, November 10-12, 2026

Eric Easom, Co-Founder, Chairman, President and

Form 4 AN2 Therapeutics, Inc. For: Oct 12 Filed by: Marks Gilbert Lynn

Tue, 13 Oct 2026 17:13:00 -0400

si-local-file:///var/storage/secattach/20261013/27181927.html

Form 4 AN2 Therapeutics, Inc. For: Oct 12 Filed by: Martin Patricia A.

Tue, 13 Oct 2026 17:13:00 -0400

si-local-file:///var/storage/secattach/20261013/27181926.html

Form 4 AN2 Therapeutics, Inc. For: Oct 12 Filed by: Aziz Kabeer

Tue, 13 Oct 2026 17:12:00 -0400

si-local-file:///var/storage/secattach/20261013/27181921.html

Gates Foundation extends funding for AN2 and GSK tuberculosis research

Mon, 28 Sep 2026 07:02:36 -0400

AN2 Therapeutics, Inc. (Nasdaq: ANTX) announced that the Gates Foundation has awarded an extension of funding to support the company's research activities under its ongoing tuberculosis (TB) collaboration with GSK, focused on the development of boron-based leucyl-tRNA synthetase (LeuRS) inhibitors.

The collaboration aims to advance boron-based LeuRS inhibitors as potential treatments for TB, a disease that caused an estimated 10.7 million illnesses worldwide in 2024, according to the World Health Organization.

Vince Hernandez, Senior Vice President of Research and Head of Chemistry at AN2 Therapeutics, said the additional funding "reflects the progress made by the collaboration and the potential of boron chemistry

AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK

Mon, 28 Sep 2026 07:00:00 -0400

Funding from Gates Foundation supports continued advancement of boron-based LeuRS inhibitors for the treatment of tuberculosis

MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage pharmaceutical company focused on the discovery and development of small molecule therapeutics derived from its boron chemistry platform, today announced that the Gates Foundation has awarded an extension of funding to support AN2 Therapeutics' research activities under its ongoing tuberculosis (TB) research collaboration with GSK focused on the development of boron-based leucyl-tRNA synthetase (LeuRS) inhibitors.

TB remains a major global public health challenge. Globally, TB is the world’s leading cause

AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK

Mon, 28 Sep 2026 07:00:00 -0400

Funding from Gates Foundation supports continued advancement of boron-based LeuRS inhibitors for the treatment of tuberculosis

TB remains a major global public health challenge. Globally, TB is the world’s leading cause

Form 4 AN2 Therapeutics, Inc. For: Sep 15 Filed by: Trenor Cameron C. III

Wed, 16 Sep 2026 17:35:00 -0400

si-local-file:///var/storage/secattach/20260916/27071274.html

AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)

Wed, 16 Sep 2026 17:33:00 -0400

MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (NASDAQ: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced it granted inducement equity awards to Cameron Trenor, M.D., the Company’s newly-appointed Chief Medical Officer.

The inducement awards consist of a non-qualified stock option to purchase 233,333 shares of the Company’s common stock and restricted stock units representing 116,667 shares of the Company’s common stock. The option has an exercise price of $5.36 per share, which is equal to the closing price of the Company’s common stock on the date of

AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)

Wed, 16 Sep 2026 17:33:00 -0400

Form S-8 AN2 Therapeutics, Inc.

Mon, 14 Sep 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260914/27058436.html

Form 4 AN2 Therapeutics, Inc. For: Sep 09 Filed by: Readnour Robin Shane

Fri, 11 Sep 2026 19:46:00 -0400

si-local-file:///var/storage/secattach/20260911/27053945.html

Form 3 AN2 Therapeutics, Inc. For: Aug 24 Filed by: Trenor Cameron C. III

Thu, 27 Aug 2026 14:16:00 -0400

si-local-file:///var/storage/secattach/20260827/26988808.html

Form 3 AN2 Therapeutics, Inc. For: Aug 24 Filed by: Trenor Cameron C. III

Thu, 27 Aug 2026 14:16:00 -0400

si-local-file:///var/storage/secattach/20260827/26988808.html

AN2 Therapeutics names Cameron Trenor as chief medical officer